Evolus/$EOLS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Evolus
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- Ticker
- $EOLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 353
- Headquarters
- Newport Beach, United States
- Website
- www.evolus.com
Evolus Metrics
BasicAdvanced
$449M
-
-$0.47
1.34
-
Price and volume
Market cap
$449M
Beta
1.34
52-week high
$9.31
52-week low
$3.86
Average daily volume
776K
Financial strength
Current ratio
1.417
Quick ratio
0.716
Long term debt to equity
-4.294
Total debt to equity
-4.379
Interest coverage (TTM)
-1.07%
Profitability
EBITDA (TTM)
-8.275
Gross margin (TTM)
66.06%
Net profit margin (TTM)
-9.56%
Operating margin (TTM)
-5.41%
Effective tax rate (TTM)
-2.54%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-4.37%
Return on equity (TTM)
93.47%
Valuation
Price to revenue (TTM)
1.368
Price to book
-11.89
Price to tangible book (TTM)
-4.25
Price to free cash flow (TTM)
-54.07
Free cash flow yield (TTM)
-1.85%
Free cash flow per share (TTM)
-0.126
Growth
Revenue change (TTM)
13.87%
Earnings per share change (TTM)
-48.04%
3-year revenue growth (CAGR)
20.78%
3-year earnings per share growth (CAGR)
-24.70%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Analyst projections of the future price of Evolus stock.
Bulls say / Bears say
Q3 revenue grew 13% year on year to $78 million; toxin sales rose 11% and HA gel revenue nearly 40%, so both established and newer products are contributing. (Business Wire)
Adjusted EBITDA was positive for a fourth straight quarter at $1.2 million, a $4.2 million year-on-year improvement, while Evolus lowered its full-year expense outlook. This points to better operating leverage as the business grows. (Business Wire)
Evolus remains loss-making on a GAAP basis: it reported an $8.4 million operating loss and a $12.5 million net loss in Q3. It also used $15.5 million of cash in operations in the first nine months, with $41.7 million in cash at quarter end. (StreetInsider)
Jeuveau made up $70.1 million of Q3’s $78 million revenue, and Evolus relies on Daewoong as its sole manufacturer. A supply disruption or loss of key rights could therefore put much of its current sales base at risk. (Business Wire, StreetInsider)
The full-year revenue target depends on a sharp Q4 step-up: after $235.2 million in the first nine months, the outlook implies a 25% to 30% sequential rise in Q4. Q3 EPS also missed analyst expectations by $0.13, adding pressure to show stronger execution. (Finviz, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evolus News
AllArticlesVideos
What Evolus (EOLS) Said on Its Q3 Earnings Call
MarketBeat2 days ago
Evolus to Participate in Upcoming Investor Conferences in New York and London
Business Wire1 week ago
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
Business Wire4 weeks ago
Funds containing Evolus
Fund name | Fund size | $EOLS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.